Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatment eases menopause symptoms without hormones

NCT ID NCT07246616

Symptom relief Sponsor: Institute for Social Security, Republic of San Marino Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment for postmenopausal women with vaginal atrophy—a condition causing dryness, burning, and pain. Researchers combined CO₂ laser therapy with a collagen cream to see if it worked better than laser alone. Sixty women aged 35 to 75 took part, and the team measured symptom relief and changes in vaginal bacteria after 30 and 60 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Jun 2024

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 75 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postmenopausal women with absence of menstrual cycle for at least 12 months, diagnosed with vulvovaginal atrophy (VVA) and presenting with related symptoms such as dryness, introital and deep dyspareunia, bleeding during intercourse, itching, or burning related to the severity of VVA, whether spontaneous or drug-induced (radio- or chemotherapy), either with a single symptom or a combination thereof. * Age between 35 and 75 years; * Patients unresponsive or dissatisfied with previous topical estrogen therapy, or presenting contraindications to the use of local and/or systemic estrogens. * Previous negative Pap test performed within 3 years prior to study enrollment. Exclusion Criteria: * • Pregnancy or breastfeeding; * Presence of preneoplastic or neoplastic lesions of the cervix, vagina, or vulva; * Presence of active genital and/or urinary tract infection; * Relative or absolute dermatological contraindications to laser use; * Ongoing hormonal therapy (systemic or local); * Neurological and/or psychiatric disorders; * Chronic systemic autoimmune or metabolic diseases; * Refusal to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vulva; atrophy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Atrophy postmenopausal atrophic vaginitis vulvar dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vulva; atrophy

Contacts and locations

Locations

  • UOC di Ostetricia e Ginecologia, Ospedale di Stato della Repubblica di San Marino, Istituto per la Sicurezza Sociale (ISS)

    San Marino, Borgo Maggiore, 47893, San Marino

More trials for these conditions

Other studies related to the condition(s) this trial covers.